A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
Telangiectasia hemorrágica y hereditaria; THH
Los tratamientos abarcan:
Algunos pacientes responden a la terapia con estrógenos, la cual puede reducir los episodios de sangrado. Evite tomar medicamentos anticoagulantes.
Algunos pacientes tal vez necesiten tomar antibióticos antes de someterse a procedimientos quirúrgicos o dentales. Pregúntele al médico qué precauciones debe tomar.
HHT Foundation International:
Las personas con este síndrome pueden tener un período de vida completamente normal, dependiendo de las partes del cuerpo donde se localicen las malformaciones arteriovenosas.
Consulte con el médico si su hijo presenta sangrados nasales frecuentes u otros signos de esta enfermedad.
Azuma H: Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia. J Med Invest. 2000 Aug; 47(3-4): 81-90.
Faughnan ME, Hyland RH, Nanthakumar K, Redelmeier DA: Screening in hereditary hemorrhagic telangiectasia patients. Chest. 2000 Aug; 118(2): 566-7.
Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet. 2009 Apr 1. [Epub ahead of print]
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.866.408.6885